NCT01991899View on ClinicalTrials.gov

Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.

PHASE3CompletedINTERVENTIONAL
Enrollment

1,560

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

July 31, 2016

Conditions
MeaslesMumpsRubellaVaricella
Interventions
BIOLOGICAL

MMR Bio-Manguinhos

1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline

BIOLOGICAL

MMR GlaxoSmithKline

390 children will receive 0,5 ml MMR GlaxoSmithKline

Trial Locations (1)

67030-000

Instituto Evandro Chagas, Belém

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

OTHER

NCT01991899 - Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. | Biotech Hunter | Biotech Hunter